Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Cartesian Therapeutics, Inc. (RNAC)

Inhibikase Therapeutics, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Cartesian Therapeutics, Inc. are of similar size ($229.7M and $209.3M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −94.8%. Across the 12 metrics below, Cartesian Therapeutics, Inc. leads on 7 and Inhibikase Therapeutics, Inc. on 5.

Valuation

Metric IKT RNAC Biotechnology median
P/E n/m n/m 10.60
P/S 1,005.21 125.01 9.40
P/B 1.71 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 394.78 77.39 9.02
Earnings yield (28.67%) (78.75%) (32.88%)
Free cash flow yield (16.28%) (35.43%) (23.13%)

Profitability

Metric IKT RNAC Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (51.96%) 236.88% (51.96%)
Return on assets (48.04%) (42.77%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IKT RNAC Biotechnology median
Revenue growth (TTM) 110.93% (94.81%) 6.76%
EPS growth (last fiscal year) 57.76% (11.80%) 29.88%
Revenue growth, 5-year CAGR (42.21%) (29.96%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 15.82 7.48 4.97
Net debt to EBITDA 3.44 0.89 1.01

Dividend

Metric IKT RNAC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IKT RNAC Biotechnology median
Market cap 209.30m 229.69m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack